SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is seeing significant market interest as investors anticipate the imminent 80th event data release for its Phase 3 REGAL trial, with community discussions buzzing about potential short squeezes and a possible buyout. The stock's recent momentum is driven by management's confirmed strategy to expand its immunotherapy platform beyond AML, fueling optimism about broad-market indications.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market digests strong Q1 results, which featured an earnings beat, improved vehicle margins, and aggressive Q2 delivery guidance. While retail investors are actively celebrating the company's path to profitability and substantial cash reserves, community sentiment remains highly polarized by ongoing concerns over stock price manipulation and persistent volatility in the Chinese EV sector.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is currently a focal point for investors following an influx of federal funding announcements, fueling intense debate over the stock's valuation, dilution risks, and commercial viability versus speculative hype. While bulls emphasize strong growth in bookings and the company's long-term potential in the quantum sector, bears remain skeptical, highlighting significant cash burn and concerns over whether the current momentum is sustainable.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are seeing a significant sell-off despite beating earnings and raising guidance, driven by investor anxiety over the potential impact of AI on its tax-software moat and a simultaneous announcement of a 17% workforce reduction. The community is sharply divided between those viewing the decline as a major institutional "smash and grab" overreaction to be bought for long-term value, and skeptics who fear the company's business model is being structurally undermined by emerging AI tools.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing a significant surge in momentum as the U.S. government awards the company $100 million in milestone-based funding and secures an equity stake, signaling strong validation of its neutral-atom quantum technology. The community is actively discussing the stock's potential as a long-term infrastructure play, drawing frequent comparisons to other quantum leaders and highlighting its debt-free status and strategic partnerships.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to a proposed $100 million federal funding initiative aimed at accelerating its quantum research, while community members actively debate the stock's long-term valuation and the broader implications of increased government involvement in the quantum computing sector.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors debate its premium valuation amid persistent cost pressures, while others highlight the retailer's growth in advertising and membership revenue as a long-term catalyst. The community remains divided, with many viewing current dips as a defensive buying opportunity while critics point to its high price-to-earnings ratio and sensitivity to broader economic strains.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is experiencing significant volatility following its latest earnings report, which highlighted headwinds from expiring tax credits and soft guidance. While the stock faces downward pressure, the community is debating whether the decline is an overreaction or a long-term bottoming process, with significant interest centered on the company's strategic pivot into AI-focused solid-state transformer technology.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is facing volatility as investors weigh impressive growth and rising demand against supply constraints and the risks associated with its pivot toward manufacturing custom silicon. The community remains deeply divided, with many debating whether the current pullback offers a strategic entry point for long-term growth in the AI infrastructure cycle or if the stocks valuation remains detached from fundamentals.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is experiencing intense volatility following a strong earnings report as investors weigh impressive growth and capital return programs against concerns over China market restrictions and profit-taking activity. The community remains deeply divided, with many traders debating whether recent price action is driven by sophisticated market manipulation and options hedging or by the stock's massive market cap creating natural resistance to further upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in ImageneBio, Inc. (NASDAQ:IMA) Increases By 51.7%

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totaling 587,281 shares, a growth of 51.7...

<ul class="summary-bullets"><li>ImageneBio said it plans to use the proceeds to support the development of IMG-007 for alopecia areata and late-stage work in atopic dermatitis.</li><li>The biotech firm is currently conducting its Phase 2b ADAPTIVE trial for IMG-007, with topline results expected in 2027.</li><li>ImageneBio will present the latest data from the study at the Annual Society for Investigative Dermatology Meeting in May.</li></ul>Shares of ImageneBio, Inc. (IMA) surged more than 24% on Monday, crossing their 50-day moving average (50-DMA) for the first time since Feb. 27, 2026, after the biotech firm announced fresh funding from institutional investors in the form of a $30 million private placement.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AIMA"><img src="https://news.stocktwits-cdn.com/IMA_jpg_91814193cc.webp" alt="IMA.jpg"></a>Source: TradingViewImageneBio said it plans to use the proceeds to support the development of IMG-007 for alopecia areata and late-stage work in atopic dermatitis. The deal involves the sale of pre-funded warrants to purchase over 5.7 million shares at $5.199 per share.The financing round is led by new investor Coastlands Capital, with participation from Trails Edge Capital Partners and existing backers Omega Funds and OrbiMed.<h2 class="st-heading-2">What’s The Latest On Drug To Treat Dermatitis?</h2>ImageneBio is currently conducting a Phase 2b ADAPTIVE trial for IMG-007, with topline results expected in 2027. The study, which began enrollment in mid-2025 across North America, continues to show a favorable safety and tolerability profile, as indicated by a recent blinded review. A Blinded review means the people running a clinical trial do not know which patients are receiving the treatment.IMG-007 has been well tolerated across studies involving more than 150 patients, with no serious safety concerns reported. Reported side effects have been minimal, with very low rates of mild injection-site reactions.The company has also recently submitted a protocol update to expand dosing strategies and explore more patient-friendly treatment schedules. ImageneBio will present the latest data from the study at the Annual Society for Investigative Dermatology Meeting in May.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/IMA">IMA</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One bullish user said buying the stock was a “no-brainer,” comparing the company’s market cap to the funding amount.<stembedurl>https://stocktwits.com/Jimmytrader35/message/650097652</stembedurl>Another user expects the stock to climb all week.<stembedurl>https://stocktwits.com/Jimmytrader35/message/650131942</stembedurl>Year-to-date, the stock has gained around 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cag-stock-crashes-to-near-17-year-lows/cZJ85DBRIun">CAG Stock Crashes To Near 17-Year Lows, But Retail Sees ‘Buying Opportunity Of A Decade’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally?

ImageneBio shares jumped to their highest levels in more than a month after the company announced a $30 million fundraising from institutional investors.

Equity

ImageneBio $30 Million Private Placement Ignites Stock

ImageneBio shares rise after a $30 million private placement to advance IMG-007 development for atopic dermatitis and alopecia areata.read more...

ImageneBio (NASDAQ:IMA) Stock Price Down 8.5%  - Here's Why

ImageneBio (NASDAQ:IMA) Shares Down 8.5% - Here's What Happened...

Atlas Venture Life Science Advisors LLC Buys New Position in ImageneBio, Inc. $IMA

Atlas Venture Life Science Advisors LLC bought a new position in shares of ImageneBio, Inc. (NASDAQ:IMA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F...

Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to "Hold"

Wall Street Zen upgraded ImageneBio from a "strong sell" rating to a "hold" rating in a report on Saturday...

BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA

BML Capital Management LLC purchased a new position in ImageneBio, Inc. (NASDAQ:IMA - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities...

ImageneBio (NASDAQ:IMA) Shares Up 2.4% - Still a Buy?

ImageneBio (NASDAQ:IMA) Stock Price Up 2.4% - Still a Buy...

ImageneBio (NASDAQ:IMA) Trading Up 0.5% - Should You Buy?

ImageneBio (NASDAQ:IMA) Shares Up 0.5% - Here's Why...

Insider Buying: ImageneBio (NASDAQ:IMA) Director Acquires 16,000 Shares of Stock

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report) Director Joseph Slattery acquired 16,000 shares of the company's stock in a transaction on Wednesday, December 24th. The shares were bought at an...

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

IMA
ImageneBio, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest IMA News

IMAImageneBio, Inc.